Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + Nivolumab in PD-1 Resistant NSCLC
NCT03262779Phase 2Completed
- Sponsor
- Yale University
- Start
- Jul 2017
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yale University. Primary endpoint: Objective Response Rate (RECIST v1.1) up to 4 years. Started Jul 2017; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03262779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262779.